Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Sells Shares Under 10b5-1 Trading Plan

CRISPR Therapeutics CEO Samarth Kulkarni sold a total of 30,000 common shares in multiple transactions under a pre-arranged 10b5-1 trading plan.

Summary

• Samarth Kulkarni, CEO of CRISPR Therapeutics, sold 23,121 common shares at a weighted average price of $55.43.
• He also sold 6,879 common shares at a weighted average price of $56.27.
• These sales were executed on November 11, 2024, under a Rule 10b5-1 trading plan adopted on June 13, 2024.
• Following these transactions, Kulkarni directly owns 196,540 common shares and indirectly owns 85,622 shares through The Kulkarni 2023 GRAT.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan. It is neither particularly positive nor negative, but a neutral event.

Risks

• Sales by a company's CEO could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Executive stock sales are a common occurrence, especially under pre-arranged trading plans like 10b5-1, and are often viewed as part of normal executive compensation and portfolio management. The market reaction will depend on the overall sentiment towards the company and the size of the transaction relative to the executive's holdings.

Comparison to Industry Standards

• Many executives at publicly traded companies use 10b5-1 trading plans to sell shares, which is a standard practice to avoid accusations of insider trading.
• The size of the sale is relatively small compared to the total outstanding shares of CRISPR Therapeutics, and is not unusual for a CEO's portfolio management.
• Comparable companies in the biotech sector often see similar transactions by their executives.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, but the pre-arranged nature of the sales should mitigate any significant negative reaction from shareholders.

Key Dates

Keywords

CRISPR Therapeutics, Samarth Kulkarni, stock sale, 10b5-1 trading plan, insider trading, share transaction, executive sale